RT Journal Article
SR Electronic
T1 Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 378
OP 379
DO 10.1136/thoraxjnl-2015-207497
VO 71
IS 4
A1 Taimeh, Ziad
A1 Hertz, Marshall I
A1 Shumway, Sara
A1 Pritzker, Marc
YR 2016
UL http://thorax.bmj.com/content/71/4/378.abstract
AB Objective Lung transplantation is the ultimate treatment for end-stage pulmonary sarcoidosis. Post-transplant survival outcomes remain unclear.Methods Survival models were used to assess survival and graft outcomes in patients with sarcoid among 20 896 lung transplants performed in the USA.Results 695 lung recipients were transplanted for pulmonary sarcoidosis. Sarcoid lung recipients had similar median survival rate (69.7 months (IQR 60.2–79.3)) compared with the non-sarcoid lung recipients (63.1 months (IQR 61.4–64.8), p=0.88). In multivariate Cox regression, sarcoidosis was not independently associated with worse mortality (HR 0.96 (95% CI 0.85 to 1.08), p=0.51). Among the sarcoid lung recipients, double lung transplantation (HR 0.76 (0.58 to 0.99), p=0.04) and lung allocation score era (HR 0.74 (0.56 to 0.97), p=0.03) were associated with improved survival.Conclusions Recipients of lung transplants for pulmonary sarcoidosis had similar outcomes compared with non-sarcoid lung recipients.